- Home
- EXEL vs SIGA Comparison
EXEL vs SIGA Comparison
Compare EXEL & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- SIGA
- Stock Information
- Founded
- EXEL 1994
- SIGA 1995
- Country
- EXEL United States
- SIGA United States
- Employees
- EXEL N/A
- SIGA N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- EXEL Health Care
- SIGA Health Care
- Exchange
- EXEL Nasdaq
- SIGA Nasdaq
- Market Cap
- EXEL 11.3B
- SIGA 422.9M
- IPO Year
- EXEL 2000
- SIGA 1997
- Fundamental
- Price
- EXEL $44.08
- SIGA $6.52
- Analyst Decision
- EXEL Buy
- SIGA
- Analyst Count
- EXEL 18
- SIGA 0
- Target Price
- EXEL $43.00
- SIGA N/A
- AVG Volume (30 Days)
- EXEL 3.3M
- SIGA 418.3K
- Earning Date
- EXEL 08-05-2025
- SIGA 07-31-2025
- Dividend Yield
- EXEL N/A
- SIGA 9.02%
- EPS Growth
- EXEL 237.58
- SIGA N/A
- EPS
- EXEL 2.20
- SIGA 0.67
- Revenue
- EXEL $2,298,922,000.00
- SIGA $120,330,310.00
- Revenue This Year
- EXEL $9.37
- SIGA N/A
- Revenue Next Year
- EXEL $11.05
- SIGA $95.31
- P/E Ratio
- EXEL $19.98
- SIGA $9.91
- Revenue Growth
- EXEL 24.49
- SIGA N/A
- 52 Week Low
- EXEL $21.82
- SIGA $4.95
- 52 Week High
- EXEL $49.62
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- EXEL 57.96
- SIGA 57.63
- Support Level
- EXEL $42.66
- SIGA $6.01
- Resistance Level
- EXEL $49.62
- SIGA $6.49
- Average True Range (ATR)
- EXEL 1.58
- SIGA 0.25
- MACD
- EXEL 0.10
- SIGA 0.00
- Stochastic Oscillator
- EXEL 43.24
- SIGA 75.32
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.